Genetic Analysis AS (GA) is positioned to become a world leader within the field of molecular diagnostics of diseases related to gut imbalances. By utilizing the DNA-based GA-map™ array technology, profiles of a patient’s gut microbiota is quickly generated and can be related to various health conditions.
Jan 10 2014 : The GA-map™ IBS Dysbiosis Test is now CE marked. Until the GA-map™ analysis is implemented in external laboratories, we can recieve samples for analysis in the Genetic Analysis laboratory in Oslo.
Oct 14 2013 : Norwegian molecular diagnostics company Genetic Analysis launched the GA-map™ IBS Dysbiosis Test at the United European Gastroenterology Week in Berlin.
Oct 1 2013 : Norwegian molecular diagnostics company Genetic Analysis today announced that it has secured $2 million to fund the CE-marking and launch of its DNA-based GA-map™ test for dysbiosis in IBS patients. The funding follows the appointment of industry veteran Kari Stenersen as CEO.